BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) from a strong sell rating to a sell rating in a report released on Friday.

A number of other research firms also recently issued reports on CRBP. Noble Financial reissued a buy rating on shares of Corbus Pharmaceuticals Holdings in a report on Saturday, May 6th. Cantor Fitzgerald set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings and gave the company a buy rating in a report on Tuesday, May 9th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Corbus Pharmaceuticals Holdings has an average rating of Buy and a consensus price target of $20.50.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ CRBP) traded up 3.79% during mid-day trading on Friday, reaching $6.85. The company had a trading volume of 686,190 shares. The company’s 50-day moving average price is $6.24 and its 200-day moving average price is $7.04. Corbus Pharmaceuticals Holdings has a 52-week low of $4.00 and a 52-week high of $10.78. The company’s market capitalization is $344.01 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 107.10%. On average, analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.66) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/26/corbus-pharmaceuticals-holdings-inc-crbp-upgraded-to-sell-by-bidaskclub.html.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Corbus Pharmaceuticals Holdings by 24.5% in the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after buying an additional 307,979 shares in the last quarter. State Street Corp increased its stake in Corbus Pharmaceuticals Holdings by 2,998.2% in the second quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 569,662 shares in the last quarter. Northern Trust Corp increased its stake in Corbus Pharmaceuticals Holdings by 814.3% in the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after buying an additional 429,584 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Corbus Pharmaceuticals Holdings by 5.5% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 426,280 shares of the biopharmaceutical company’s stock worth $2,686,000 after buying an additional 22,394 shares in the last quarter. Finally, Artal Group S.A. acquired a new stake in Corbus Pharmaceuticals Holdings during the second quarter worth about $1,575,000. 28.63% of the stock is owned by hedge funds and other institutional investors.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.